CJC-1295 and Ipamorelin

Quick summary

CJC-1295 is a modified analog of growth-hormone-releasing hormone (GHRH) that stimulates the pituitary to secrete growth hormone (GH). Ipamorelin is a synthetic pentapeptide that activates the ghrelin receptor (GHS-R1a) and produces GH release through a different intracellular pathway. The two compounds are frequently discussed together because they act on complementary receptor systems, and the hypothesis is that combining them produces greater GH output than either alone.

Neither compound is approved in the United States, the European Union, the United Kingdom, Australia, or Canada. Both reached early-phase clinical studies and were discontinued before regulatory filing. Most of the evidence cited in biohacking and wellness contexts comes from those early studies or from anecdotal reports, not from registered, adequately powered trials.

CJC-1295: background and development

Native GHRH(1-29) is the 29-residue N-terminal fragment of growth-hormone-releasing hormone produced in the hypothalamus. It binds the GHRH receptor on pituitary somatotrophs and triggers GH release, but it is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) in plasma with a half-life of only a few minutes. This short duration made native GHRH impractical as a pharmaceutical.

CJC-1295 is the name assigned to two related compounds developed by ConjuChem, a Canadian biotechnology company:

• CJC-1295 without DAC (also called Mod GRF 1-29 or "ModGRF"): a GHRH(1-29) analog with four amino-acid substitutions that protect against DPP-4 cleavage. Half-life is approximately 30 minutes. Requires more frequent dosing.
• CJC-1295 with DAC (drug affinity complex): the same analog with an added maleimidopropionic acid (MPA) group that covalently binds to circulating albumin. This extends the half-life to approximately 6-8 days in early Phase I/II reports, allowing weekly or less frequent dosing.^[1]

ConjuChem conducted Phase I and Phase IIb studies of CJC-1295 with DAC in healthy adults and in patients with HIV-associated lipodystrophy. The Phase IIb program showed increases in mean GH and IGF-1 levels but did not progress to a Phase III trial or regulatory filing. The company ceased active development, and no approved product emerged.

Ipamorelin: background and development

Ipamorelin is a synthetic pentapeptide developed by Novo Nordisk in the late 1990s. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. It belongs to the growth-hormone secretagogue (GHS) class: compounds that activate the GHS-R1a (ghrelin receptor) to stimulate GH release from the pituitary.

Ipamorelin's principal pharmacological distinction from earlier GHRPs (such as GHRP-2 and GHRP-6) is its selectivity. In early animal and human studies, it produced significant GH release with minimal or no elevation of cortisol, prolactin, or ACTH at doses that effectively stimulated GH.^[4] This selectivity was the rationale for its development.

Novo Nordisk evaluated Ipamorelin for post-operative ileus (impaired gut motility after abdominal surgery) in Phase II and Phase III trials. The compound did not achieve approval for this indication. Licensing activities occurred after Novo Nordisk discontinued development, but no product reached market authorization in any jurisdiction.

The combination: rationale and evidence limits

CJC-1295 stimulates GH via the GHRH receptor; Ipamorelin stimulates GH via the ghrelin receptor. These are two distinct signaling pathways in the pituitary somatotroph. The pharmacological logic is that stimulating both pathways simultaneously could produce GH release that exceeds what either pathway produces alone, by analogy to the potentiation seen in experimental models combining GHRH and ghrelin-pathway agonists.

What the evidence does not show: there are no published, registered, adequately powered randomized controlled trials of the CJC-1295 plus Ipamorelin combination in humans. The combination is popular in biohacking and anti-aging communities, and vendor-published material describes it as having synergistic effects on GH release, body composition, recovery, and sleep quality. These claims have not been tested in controlled studies. The evidence for each compound separately is limited to early-phase studies with small samples and short follow-up. The evidence for the combination is effectively anecdotal.

Detailed mechanistic discussion is in: Mechanism of Action: GHRH and Ghrelin Pathways

Pharmacokinetics in brief

A full discussion of PK, the DAC mechanism, and what is not yet known is in: Half-Life and Pharmacokinetics

IGF-1 elevation: what the early data showed

The Phase I study by Teichman et al. (2006) reported that a single injection of CJC-1295 with DAC in healthy adults produced sustained mean GH elevation for up to 6 days and increased serum IGF-1 levels by 20-60% above baseline, depending on dose, with effects lasting for 1-2 weeks.^[1] A subsequent protein-profiling study (Sackmann-Sala et al., 2009) confirmed IGF-1 changes and described secondary serum protein alterations consistent with GH-axis activation.^[3]

These findings are frequently cited as evidence of efficacy. What they actually demonstrate is pharmacodynamic activity: the peptide does what it is designed to do at the receptor level. Whether sustained supraphysiological IGF-1 elevation translates to clinically meaningful and safe benefit in healthy adults has not been tested in long-term controlled trials.

Safety overview

Adverse events reported in the small Phase I/II studies of CJC-1295 included injection-site reactions, transient flushing, and headache. No serious unexpected adverse events were reported in the published literature at the doses tested. However, these studies were short in duration and enrolled small numbers of participants; they were not designed or powered to detect rare or long-term adverse events.

The theoretical concern with sustained supraphysiological GH and IGF-1 stimulation relates to conditions associated with acromegaly: insulin resistance, fluid retention, arthropathy, cardiomegaly, and, in preclinical models, promotion of tumor growth. Long-term controlled data for either compound in humans do not exist.

Safety discussion, including what early-phase studies actually reported, is in: Safety Profile and Evidence Gaps

Regulatory status

CJC-1295 and Ipamorelin are not approved in any jurisdiction reviewed on this site (US, EU, UK, Australia, Canada). Both compounds are sold by research chemical vendors and are used in non-clinical settings without physician supervision in some markets. This constitutes unapproved use of compounds whose long-term safety has not been established. Use the region switcher above to view agency-specific details.